about
Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III studyNanomedicines of Hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis.Disorders of glucose metabolism in patients infected with human immunodeficiency virus.Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion.Enhancing insulin action: from chemical elements to thiazolidinediones.Treating type 2 diabetes--today's targets, tomorrow's goals.Treatment of vascular risk factors in patients with a diagnosis of Alzheimer's disease: a systematic review.Oral combination therapy for type 2 diabetes.Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseasesDevelopmental Programming: Prenatal and Postnatal Androgen Antagonist and Insulin Sensitizer Interventions Prevent Advancement of Puberty and Improve LH Surge Dynamics in Prenatal Testosterone-Treated Sheep.Saroglitazar, a novel PPARα/γ agonist with predominant PPARα activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models.The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.59th annual meeting of the American Diabetes Association. June 19-22, 1999, San Diego, CA, USA.Effect of ligand of peroxisome proliferator-activated receptor gamma on the biological characters of hepatic stellate cells.Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action.A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetesPPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes.High glucose represses β-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor γ signaling.Effect of thiazolidinediones on the erythropoeitic and germinal cells in the male wistar rats.Insulin-sensitizing action of rosiglitazone is enhanced by preventing hyperphagia.PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes.DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.Effects of retinoids and thiazolidinediones on proliferation, insulin release, insulin mRNA, GLUT 2 transporter protein and mRNA of INS-1 cells.Development and validation of a repharsed phase- HPLC method for simultaneous determination of rosiglitazone and glimepiride in combined dosage forms and human plasma.Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects.Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone.Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect.Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs.Which is the eligible patient to be treated with pioglitazone? The expert view.Effects of pioglitazone and/or simvastatin on circulating TNFα and adiponectin levels in insulin resistance.Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects.The effects of rosiglitazone treatment on the fibrinolytic system in patients with type 2 diabetes mellitus.Pattern of thiazolidinedione exposures reported to Texas poison centers during 1998-2004.Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus.Voltammetric Determination of Rosiglitazone in Pharmaceutical Preparations and Human Plasma
P2860
Q24628969-4122CC02-5CA1-4F4D-AE4A-C5A8B60F18ADQ30697447-034E0C16-197D-4C2D-8580-0B24F94EE460Q34092346-0D493B0E-4672-46DE-B68F-7571DAEE1931Q34126249-985FCCC8-E93C-4A34-92E3-BD67181446E2Q34268346-E6B87B72-9751-4325-97E7-F4C4B06CBB7FQ34422790-C6AFFD94-1A47-43DE-AAB4-B263487355D0Q34484520-EED98A2C-03D1-4EC9-84F4-8EEF0CEABC11Q34906456-6A4E7D3F-A3A4-4ABC-9791-3501FC47D98AQ35045743-9DCF1125-1E56-4B4F-87B5-C2E68BD0FC75Q35224775-BB9C11AA-9A9B-455F-9418-65FDC8D06909Q35763642-9E04C1E1-7863-485B-8E0E-99CABF16858EQ35822331-96FCAB98-E990-4090-8937-F6AB6B5EC299Q35827269-5D1EAB82-B813-4F4E-9C5A-AB75D7330F6BQ36181381-6C3A4C65-B6DB-44FB-A2BB-4A19C862A4E8Q36190403-18E6D776-CB90-494D-8C35-39F174ACF59AQ36319330-06E6B1AD-ADB2-46ED-8299-412CCB19F8BFQ36536205-E6B21F7C-293E-49CD-B484-106DEBB7C861Q36787677-24CF5B77-B5AA-4F8F-98BD-14F86A2E6BCDQ36847318-4EB019BE-3D9D-4803-86F2-9FF31A76A5D5Q37251086-576AC129-660F-4C9B-AC38-D23AE780960DQ38260621-C3AF1B6D-45A4-488A-8B47-52C0DA2DB591Q38299766-AA1F2552-C4CB-46CB-B0BE-A3DDEAD98E45Q38363586-AEAFADEC-0170-461F-90CE-3C1D407ECE9CQ40671125-981D91BE-78C2-473E-B70C-317FBFCEB6A8Q40787457-F0A1EDDF-9576-4B0B-B17D-8FCAADBF6C44Q42181188-DFD8E0E2-8F12-4C76-B83D-B6D2F97A1A12Q42284127-7A9EB735-39C1-4482-A06F-36F6B1F2DCFBQ44013976-2FF7BF94-D220-465B-A867-7CF84CDEF006Q44460156-49535317-DED7-4527-BB37-825F3A15CED3Q44580484-E61AACD1-C788-4CAB-8A25-093B3D2BCA07Q45360810-D8B660AF-D759-424B-AA54-BE14593B729CQ46453289-987392F9-FD92-4955-8ACA-078CD5D69A8AQ46607009-31E4C2B0-2AB4-468A-9F94-88AD6CCE0411Q46917480-A8EACC3B-7709-43FB-B852-F698FD394D48Q51779164-6A6E73C6-D837-4160-8A43-D36478C866A1Q51805408-CDE4D657-EB1A-4D43-B170-D24F33E25796Q58179328-437F20E3-8AF5-4B60-9AAF-B66527E6F567
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Rosiglitazone.
@ast
Rosiglitazone.
@en
type
label
Rosiglitazone.
@ast
Rosiglitazone.
@en
prefLabel
Rosiglitazone.
@ast
Rosiglitazone.
@en
P1433
P1476
Rosiglitazone.
@en
P2093
Balfour JA
Plosker GL
P304
921-30; discussion 931-2
P356
10.2165/00003495-199957060-00007
P577
1999-06-01T00:00:00Z
P6179
1046411976